La vendita allo scoperto per UiPath dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di UiPath. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

UiPath (NYSE:PATH) Azioni, Report sulle vendite allo scoperto

UiPath

UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

UiPath Inc

Pathfinder Bancorp Inc

PATHFINDER CELL THERAPY by Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy Inc

Pathfinder Ventures Inc

PATHFINDER VENTURES INC by PATHFINDER VENTURES INC.

Pathward Financial Inc

Ark Funds, led by Cathie Wood, is one of the most well-known fund managers thanks to its actively managed ETFs that focus on future growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">areas of innovation.</a>
Two of the fund's ETFs celebrate their 10th anniversaries on Thursday. Here's a look back at the funds' launch and how they've performed over the last 10 years.
Ark Innovation: Wood and<a href="https://www.benzinga.com/topic/ark-funds"> Ark Funds launched</a> the Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) on Oct. 31, 2014. The fund has grown to become the most well-known and largest of the company's funds, with $5.78 billion in assets under management.
"ARRK is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies that are relevant to the Fund's investment theme of disruptive innovation," the company's <a href="https://www.ark-funds.com/funds/arkk">website </a>says.
Disruptive innovation themes include autonomous mobility, precision therapies, next gen cloud, neural networks, intelligent devices, digital wallets, digital assets, smart contracts and multiomic technologies, according to the company.
"ARK defines ‘disruptive innovation' as the introduction of a technologically enabled new product or service that potentially challenges the way the world works."
Here are the current top 10 holdings in the ARKK ETF and their percent of net assets:
<ol>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>Shopify Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
Since the fund's inception, the ETF is up 161.4%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500.
Here's a look at how the returns of ARKK stack up against SPY, which is the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-etf-hits-milestone-as-all-time-highs-conti">oldest and largest </a>U.S. ETF, over time:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>+19.9%</td>
<td>+36.2% </td>
</tr>
<tr>
<td>3-Year</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5-Year</td>
<td>+2.6% </td>
<td>+15.8%</td>
</tr>
<tr>
<td>Since ARKK Inception 10/31/14</td>
<td>+10.2%</td>
<td>+13.2% </td>
</tr>
</tbody>
</table>
</figure>
The chart below from <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro </a>shows the 10-year return of ARKK.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1003" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" alt="" class="wp-image-624517" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" sizes="(max-width: 1003px) 100vw, 1003px" /></a></figure>
For comparison, here is the 10-year chart of the SPY. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" alt="" class="wp-image-624522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Read Next: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">EXCLUSIVE: Cathie Wood Tells Benzinga Why Tesla Should Trade As A Tech Stock</a>
ARK Genomic: The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) was also launched by Ark Funds on Oct. 31, 2014. The fund currently has $1.33 billion in assets under management.
"ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution," the company's <a href="https://www.ark-funds.com/funds/arkg">website </a>says.
Themes for the genomics ETF include precision therapies, multiomic technologies, programmable biology, neural networks, next gen cloud and adaptive robotics, according to the company.
Here are the current top 10 holdings in the ARKG ETF and their percent of net assets:
<ol>
<li>Twist Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>CRISPR Therapeutics: 7.0%</li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
Since the fund's inception, the ETF is up 38.9%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust.
Here's a look at how the returns of ARKG stack up against SPY over time. &nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>-7.9% </td>
<td>+36.2%</td>
</tr>
<tr>
<td>3-Year</td>
<td>-29.9%</td>
<td>+11.8% </td>
</tr>
<tr>
<td>5-Year</td>
<td>-1.9% </td>
<td>+15.8% </td>
</tr>
<tr>
<td>Since ARKG inception 10/31/14</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
Here is the 10-year chart of ARKG. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" alt="" class="wp-image-624525" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Why It's Important: The charts above show that ARKK and ARKG both experiences several years of strong growth and returns for investors, but have underperformed the broader S&amp;P 500 market index in recent years.
The ETFs were once among the most talked about funds, and the company&#8217;s daily trading activity often moved stocks higher, given Wood's outperformance years ago.
While the S&amp;P 500 ETF rebalances quarterly, the actively managed funds complete trades almost every day. Often, the average cost of shares rises over time for stocks that are going up, potentially hurting the gains.
Ark Funds typically invests in companies that it believes will have strong growth over the next five to ten years, which means the funds&#8217; returns can sometimes take years to pay off.
Wood has been early to many themes, including buying shares of NVIDIA Corporation for around $5 in 2014, before the most recent stock split. The fund later sold out of its position in late 2022 and early 2023 and<a href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early"> missed out on huge gains </a>over the last nearly two years.
The fund manager was also early in the Tesla growth story, <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">predicting a $4,000 price target</a> for the electric vehicle company back in February 2018. While Wood was laughed at for the price prediction at the time, the stock would hit the target on a split-adjusted basis in January 2021.
Getting the Tesla prediction right helped elevate Wood's status as a fund manager and led to increased interest in the Ark Funds ETFs.
Although interest in Ark Funds ETFs may have cooled in recent years, many investors still recall their impact and continue to track daily trading activity, watching closely which stocks Wood selects to hold for the next five to 10 years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don&#8217;t?</a></li>
</ul>
Image courtesy of Ark Invest and Shutterstock.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

As part of its comprehensive digital transformation strategy, Omega Healthcare uses the UiPath Platform, including the AI Trust Layer and security governance features, to securely optimize workflows, enhance business value, stimulate growth, and increase profit margins for its clients.&nbsp;

News

UiPath Says It Is Transforming Operations For Omega Healthcare Through AI-powered Automation

JP Morgan analyst Mark Murphy maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Overweight and lowers the price target from $19 to $17.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on UiPath, Lowers Price Target to $17

Wells Fargo analyst Michael Turrin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and lowers the price target from $15 to $13.

Wells Fargo Maintains Equal-Weight on UiPath, Lowers Price Target to $13

Analysts' ratings for UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.5, a high estimate of $18.00, and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 4.87% from the previous average price target of $14.78.
<img src="https://www.benzinga.com/files/images/story/2024/1729684889_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of UiPath's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to UiPath. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UiPath's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of UiPath's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>All You Need to Know About UiPath</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>Understanding the Numbers: UiPath's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining UiPath's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.07% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: UiPath's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -27.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.46%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): UiPath's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: UiPath's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss UiPath Stock

10 analysts have expressed a variety of opinions on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UiPath, revealing an average target of $15.5, a high estimate of $18.00, and a low estimate of $14.00. Marking an increase of 4.87%, the current average surpasses the previous average price target of $14.78. 
<img src="https://www.benzinga.com/files/images/story/2024/1729684833_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive UiPath. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to UiPath. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for UiPath's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into UiPath's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>Discovering UiPath: A Closer Look</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>Understanding the Numbers: UiPath's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, UiPath showcased positive performance, achieving a revenue growth rate of 10.07% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: UiPath's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -27.22%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.46%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): UiPath's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: UiPath's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On UiPath Through 10 Analysts

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Hold.

Reiteration

Needham Reiterates Hold on UiPath

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 23.76 million shares sold short, which is 5.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 4.90%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About UiPath?

Investors with a lot of money to spend have taken a bullish stance on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PATH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for UiPath.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 25%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $156,000, and 2 are calls, for a total amount of $106,400.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.5 to $25.0 for UiPath over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for UiPath's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UiPath's whale activity within a strike price range from $12.5 to $25.0 in the last 30 days. 
<h3>UiPath 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728315069_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.69</td>
<td>$1.41</td>
<td>$1.41</td>
<td>$17.50</td>
<td>$56.4K</td>
<td>4.6K</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$0.7</td>
<td>$0.4</td>
<td>$0.5</td>
<td>$25.00</td>
<td>$50.0K</td>
<td>5.4K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.74</td>
<td>$2.57</td>
<td>$2.6</td>
<td>$12.50</td>
<td>$26.0K</td>
<td>7.9K</td>
<td style="text-align: right;">938</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.82</td>
<td>$2.57</td>
<td>$2.6</td>
<td>$12.50</td>
<td>$26.0K</td>
<td>7.9K</td>
<td style="text-align: right;">638</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.7</td>
<td>$2.56</td>
<td>$2.6</td>
<td>$12.50</td>
<td>$26.0K</td>
<td>7.9K</td>
<td style="text-align: right;">538</td>
</tr>
</tbody>
</table>

<h3>About UiPath</h3>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>UiPath's Current Market Status</h3>
<ul>
<li>With a volume of 1,657,785, the price of PATH is down -2.2% at $12.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 53 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UiPath options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

UiPath's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bearish move on UiPath. Our analysis of options history for UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) revealed 11 unusual trades.
Delving into the details, we found 18% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $666,810, and 5 were calls, valued at $225,186.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $12.5 for UiPath during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UiPath's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UiPath's substantial trades, within a strike price spectrum from $10.0 to $12.5 over the preceding 30 days.
<h3>UiPath Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727295350_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.65</td>
<td>$1.6</td>
<td>$1.65</td>
<td>$12.00</td>
<td>$445.7K</td>
<td>8.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$10.00</td>
<td>$69.2K</td>
<td>0</td>
<td>188</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.64</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$12.00</td>
<td>$64.0K</td>
<td>8.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PATH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.6</td>
<td>$4.2</td>
<td>$4.6</td>
<td>$10.00</td>
<td>$50.5K</td>
<td>1.7K</td>
<td>165</td>
</tr>
<tr>
<td>PATH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.64</td>
<td>$1.56</td>
<td>$1.6</td>
<td>$12.00</td>
<td>$48.0K</td>
<td>8.4K</td>
<td>2.3K</td>
</tr>
</tbody>
</table>

<h3>About UiPath</h3>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
Having examined the options trading patterns of UiPath, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of UiPath</h3>
<ul>
<li>With a volume of 5,485,144, the price of PATH is down -3.63% at $12.48. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 65 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for UiPath, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in UiPath

In the last three months, 11 analysts have published ratings on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UiPath, revealing an average target of $15.36, a high estimate of $18.00, and a low estimate of $14.00. This current average reflects an increase of 3.78% from the previous average price target of $14.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1725656441_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of UiPath among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to UiPath. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UiPath's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>Delving into UiPath's Background</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>A Deep Dive into UiPath's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: UiPath's revenue growth over a period of 3 months has been noteworthy. As of 30 April, 2024, the company achieved a revenue growth rate of approximately 15.72%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.58%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): UiPath's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.42%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): UiPath's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.99%, the company may face hurdles in achieving optimal financial performance.
Debt Management: UiPath's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 11 Analyst Insights On UiPath

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are down Friday, reversing from earlier strength after the company posted better-than-expected second-quarter financial results <a href="https://www.benzinga.com/news/earnings/24/09/40740923/uipath-reports-strong-q2-results-500m-share-repurchase-program-upbeat-guidance">after Thursday's closing bell.</a>
The Details:
UiPath beat analyst expectations on the top and bottom lines with revenue growth of more than 10% year-over-year. The company also announced a $500 million expansion to its share repurchase program and issued fiscal year revenue guidance above estimates.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/09/40733143/whats-going-on-with-celsius-holdings-stock">What&#8217;s Going On With Celsius Holdings Stock?</a>
Multiple analysts raised price targets on the stock following the print:&nbsp;
<ul>
<li>Barclays maintained UiPath with an Equal-Weight and raised its price target from $14 to $15.</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and raised the price target from $14 to $15.</li>
<li>B of A Securities analyst Brad Sills maintained a Neutral rating and raised the price target from $16 to $18.</li>
<li>Evercore ISI Group maintained UiPath with an In-Line rating and raised its price target from $13 to $16.</li>
<li>Wells Fargo analyst Michael Turrin maintained an Equal-Weight rating and raised the price target from $14 to $15.</li>
</ul>
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, UiPath shares have already surpassed the stock's average daily trading volume and 12.05% of shares are being sold short.&nbsp;
<h3 class="wp-block-heading">Will PATH Stock Go Up?</h3>
When trying to assess whether or not UiPath will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $15.33 on UiPath. The Street high target is currently at $18 and the Street low target is $14. Of all the analysts covering UiPath, no one has positive ratings, 9 have neutral ratings and no one has negative ratings.
In the last month, 9 analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/PATH/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering UiPath have performed in recent history. 
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. UiPath is 44.87% down year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about UiPath, visit <a href="https://www.benzinga.com/quote/PATH">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
PATH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, UiPath shares are down 5.11% at $12.09 at the time of publication Friday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40741553/us-judge-temporarily-blocks-bidens-latest-student-loan-relief-plan-why-it-matters">US Judge Temporarily Blocks Biden&#8217;s Latest Student Loan Relief Plan: Why It Matters</a></li>
</ul>
Image: Courtesy of UiPath, Inc.&nbsp;

Movers

What's Going On With UiPath Stock After Earnings?

DA Davidson analyst Gil Luria maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Neutral and raises the price target from $13 to $15.

DA Davidson Maintains Neutral on UiPath, Raises Price Target to $15

TD Cowen analyst Bryan Bergin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Hold and lowers the price target from $17 to $16.

TD Cowen Maintains Hold on UiPath, Lowers Price Target to $16

Shares of UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) are down Friday despite the company&#8217;s reporting <a href="https://www.benzinga.com/markets/equities/24/09/40744060/broadcom-uipath-nio-samsara-tesla-why-these-5-stocks-are-on-investors-radars-today">in-line fiscal second-quarter results</a>.
Here are some key analyst takeaways:
<ul>
<li>BMO Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585beadcb5a482000151d18b/keith-bachman">analyst Keith Bachman</a> maintained a Market Perform rating, while raising the price target from $14 to $15.</li>
<li>DA Davidson <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60784b4c4853ea0001b62900/gil-luria">analyst Gil Luria</a> reaffirmed a Neutral rating, while lifting the price target from $13 to $15.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">analyst Mark Murphy</a> reiterated an Overweight rating and price target of $19.</li>
<li>RBC Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5880b6f377f9dd00011b0ab2/matthew-hedberg">analyst Matthew Hedberg</a> maintained a Sector Perform rating and price target of $16.</li>
<li>KeyBanc Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5af19c83ca26bd0001e8af36/jason-celino">analyst Jason Celino</a> reaffirmed a Sector Weight rating on the stock.KeyBanc Capital Markets </li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
BMO Capital Markets: UiPath's quarterly results were broadly in-line with low expectations, Bachman said in a note. This is a positive, after the previous quarter's execution challenges, amid a leadership change, he added.  
The company reported annual recurring revenues of $1.55 billion. This represents 19% year-on-year growth, but a deceleration of 2 points versus the prior quarter, the analyst stated. "We are encouraged by $850M cloud ARR, representing more than half of ARR and growing by 65% y/y, demonstrating PATH's cloud-first strategy is gaining traction," he further wrote.
DA Davidson: UiPath's fiscal second-quarter results "demonstrated early success in the company&#8217;s efforts to refocus on customer centricity," Luria said. The company raised its full-year adjusted operating income guidance from $145 million to $170 million.
"The company is laser-focused on cementing its reputation as the world&#8217;s leader in enabling actions from AI insight," the analyst wrote. UiPath had several enterprise wins and the net retention among its largest accounts remains at around 120%, he added.
JPMorgan: While there are macro uncertainties, overall conditions are stabilizing compared to the previous quarter, Murphy said. Better execution and streamlining efforts helped UiPath "adapt well to the current environment," he added.
The company indicated that "restructuring efforts primarily in its central functions, with a focus on sales operations and enablement, have enhanced efficiency and agility across the organization," the analyst wrote. Management announced "modest" raises to their full-year revenue and ARR guidance and "decent upticks for operating income and FCF guidance," he further stated.
RBC Capital Markets: UiPath showed "signs of stability," following a "sizable guide-down across the board," Hedberg said. Management raised their fiscal 2025 guidance by more than the beat. The company &#8220;continues to work towards its strategic initiatives," he added.
The company continues to focus on "realigning investments to higher ROI areas," adopting a stronger strategy for growth products, and focusing on expanding its channel partner relationships, the analyst stated. "Encouragingly, management highlighted strong early adoption and positive feedback from customers for Autopilot," he further wrote.
KeyBanc Capital Markets: UiPath reported quarterly revenue and operating margin at $316.3 million and 2%. It beat consensus of $303.7 million and 0.9%, respectively. Both gross retention and net retention declined in the quarter to 97% and 115%, from 98% and 118% in the previous quarter.
The company announced another share repurchase program of up to $500 million, the analyst stated. UiPath took its full-year guidance for operating income "meaningfully higher," implying operating margins of 12%, versus the Street estimates of 9.7%, , Celino wrote.
PATH Price Action: Shares of UiPath had declined by 5.34% to $12.06 at the time of publication on Friday.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40750261/wall-street-sighs-in-relief-as-august-jobs-numbers-ease-recession-fears-small-caps-outperform-doll">Wall Street Sighs In Relief As August Jobs Numbers Ease Recession Fears: Small Caps Outperform, Dollar Trims Weekly Losses</a></li>
</ul>
Image courtesy of UiPath, Inc.

Analyst Color

Earnings Beats

UiPath Q2 Results Reflect Restructuring Benefits, Analysts Praise 'Laser-Focus' On AI

Morgan Stanley analyst Keith Weiss assumes UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight rating and announces Price Target of $15.

Initiation

Morgan Stanley Assumes UiPath at Equal-Weight, Announces Price Target of $15

RBC Capital analyst Matthew Hedberg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and maintains $16 price target.

RBC Capital Reiterates Sector Perform on UiPath, Maintains $16 Price Target

Barclays analyst Raimo Lenschow maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $14 to $15.

Barclays Maintains Equal-Weight on UiPath, Raises Price Target to $15

Wells Fargo analyst Michael Turrin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $14 to $15.

Wells Fargo Maintains Equal-Weight on UiPath, Raises Price Target to $15

Evercore ISI Group analyst Kirk Materne maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a In-Line and raises the price target from $13 to $16.

Evercore ISI Group Maintains In-Line on UiPath, Raises Price Target to $16

With robust demand, and the need for higher efficiency, the SAAS market is poised for continued growth and expansion. Therefore, it could be ideal to closely monitor high-growth SAAS stocks UiPath (PATH), CCC Intelligent Solutions (CCCS), and DocuSign (DOCU) for substantial benefit. Read on... The popularity of Software-as-a-Service (SAAS) is rapidly surging among organizations to boost their efficiency and adopt the latest technologies. SAAS has emerged as a prominent force in the technology and business landscape, and this trend is set to continue further as organizations deploy and use software.
Given the industry's strong outlook, investors could consider high-growth SAAS stocks UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>), CCC Intelligent Solutions Holdings Inc. (<a href="https://stocknews.com/stock/CCCS/">CCCS</a>), and DocuSign, Inc. (<a href="https://stocknews.com/stock/DOCU/">DOCU</a>) in November.
With the rapid transformation from traditional software applications to cloud-based software services, the Software-as-a-service market is poised to expand exponentially. Companies are increasingly investing in digital transformation and adopting trends like Vertical SaaS, DaaS, and iPaaS in order to boost their operational efficiency, cost-effectiveness, and versatility.
<a href="https://www.gartner.com/en/newsroom/press-releases/2024-05-20-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-surpass-675-billion-in-2024#:~:text=SaaS%20spending%20is%20projected%20to,consumption%20model%2C%E2%80%9D%20said%20Nag.">Gartner projected worldwide end-user spending</a> on public cloud services to increase by 20.4%, reaching $675.4 billion this year, driven by generative AI (GenAI) and application modernization.
Also, SaaS continues to dominate the cloud market in end-user spending, having a projection of 20% growth in spending to reach $247.2 billion in 2024.
Following these lucrative trends, the global Software as a Service (SaaS) market is expected to grow from $317.55 billion in 2024 to $1.23 billion by 2032, exhibiting growth at a <a href="https://www.fortunebusinessinsights.com/software-as-a-service-saas-market-102222">CAGR of 18.4%</a>. In global comparison, the U.S. SaaS market is anticipated to grow to $236.69 billion by 2032, driven by the adoption of public and hybrid cloud-based tools.
With growing needs, companies engaged in SAAS services are positioned to capitalize on the industry's bright prospects and will yield high growth in the long run. Thus, investors could scoop up high-growth SaaS companies' stocks to advance their portfolios.
Now, let's take a closer look at the fundamentals of the top <a href="https://stocknews.com/category/software-saas/">Software - SAAS</a> stocks mentioned above, beginning with the third choice.
Stock #3: UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>)
PATH provides an end-to-end automation platform offering a diverse range of international robotic process automation (RPA) solutions. It provides a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
On October 22, PATH announced a strategic partnership with Inflection AI to integrate the UiPath Platform with the new Inflection for Enterprise solution, enabling enterprises to achieve greater levels of operational efficiency and effectiveness without compromising trust and AI security options.
The strategic partnership will integrate Inflection AI within UiPath Autopilot and provide an important private cloud alternative for agentic automation tailored to the industries.
On October 15, PATH announced the integration of the UiPath Platform with the SAP Build Process Automation solution, to be sold as one of the SAP Solution Extensions. The offering will enable true enterprise-wide transformation by allowing customers to embrace a holistic view of automation across heterogeneous environments that span both SAP and non-SAP systems.
For the second that ended July 31, 2024, PATH's total revenue increased 10.1% year-over-year to $316.25 million. Its non-GAAP <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> grew 6.6% from the year-ago value to $263.18 million. Also, the company's non-GAAP net income amounted to $23.76 million or $0.04 per share for the quarter, respectively.
Furthermore, as of July 31, 2024, the company's non-GAAP adjusted free cash flow was $149.78 million.
Analysts expect PATH's revenue and EPS for the fiscal year (ending January 2026) to increase 11.3% and 10.5% year-over-year to $1.58 billion and $0.44, respectively. Further, the company has topped the consensus revenue and EPS estimates in all four trailing quarters.
PATH's stock has surged 3.1% over the past three months to close the last trading session at $12.70.
PATH's solid outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth and Quality. Within the A-rated <a href="https://stocknews.com/category/software-saas/">Software - SAAS</a> industry, PATH is ranked #11 among 18 stocks.
<a href="https://stocknews.com/stock/PATH/">Click here</a> to access additional ratings of PATH (Stability, Value, Sentiment, and Momentum).
Stock #2: CCC Intelligent Solutions Holdings Inc. (<a href="https://stocknews.com/stock/CCCS/">CCCS</a>)
CCCS operates as a software-as-a-service company for the property and casualty insurance economy. Its cloud-based SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, artificial intelligence-enabled digital workflow across the insurance economy.
On September 4, CCCS launched CCC&#xAE; Payroll, a new solution designed to streamline payroll management for collision repair shops. CCC Payroll is integrated into the CCC ONE&#xAE; platform and enables shops to track production and labor and streamline payroll within a single system, simplifying the payroll process.
The new solution simplifies the payroll process and gives greater visibility to employees.
On July 30, CCCS unveiled CCC&#xAE; Intelligent Reinspection, a new solution designed to help auto insurers streamline the review of incoming repair facility estimates, expediting repairer workflows and claims resolutions. The new solution leverages AI technology, and identifies areas for review, and provides reason codes based on insurer rules, helping reinspectors.
For the third quarter that ended on September 30, 2024, CCCS' revenues increased 7.8% year-over-year to $238.48 million. Its adjusted gross profit rose 8% from the prior year's period to $185.93 million. The company's adjusted operating income of $91.19 million reflects growth of 10.3% from the previous year's quarter.
Furthermore, the company's adjusted net income stood at $62.58 million and $0.10 per share, up 9.5% and 11.1% year-over-year, respectively. Its adjusted EBITDA increased 9.3% from the year-ago value to $101.55 million.
Analysts expect CCCS' revenue for the fourth quarter (ending December 2024) to increase 7.3% year-over-year to $245.23 million. For the same period, its EPS is expected to grow 8% year-over-year to $0.10. Further, the company topped the consensus revenue and EPS estimates in all trailing four quarters, which is remarkable.
Over the past year, the stock has gained 2.3% to close the last trading session at $10.93.
CCCS' sound fundamentals are reflected in its POWR Ratings. The stock has an overall grade of A, translating to a Strong Buy in our proprietary rating system.
CCCS has a B grade for Momentum, Stability, Sentiment, and Growth. It is ranked #4 among the 18 stocks within the A-rated Software - SAAS industry.
To see the other ratings of CCCS for Quality and Value, <a href="https://stocknews.com/stock/CCCS/">click here</a>.
Stock #1: DocuSign, Inc. (<a href="https://stocknews.com/stock/DOCU/">DOCU</a>)
DOCU provides electronic signature solutions internationally. The company provides an e-signature solution, enabling the sending and signing of agreements on various devices, Contract Lifecycle Management (CLM), Document Generation streamlines the process of generating new, custom agreements, and Gen for Salesforce.
On June 4, DOCU launched a new connector for SAP Ariba solutions that automate workflows between Docusign CLM and SAP Ariba solutions to help businesses accelerate time to value and eliminate friction in source-to-pay agreement processes. The launch enhanced DOCU's market position and firmly established the company as a leader.
On May 31, DOCU acquired Lexion, a leading AI-powered agreement management company. The acquisition strengthened DOCU's position in Intelligent Agreement Management (IAM) and added more AI-assisted capabilities to its platform, bringing more insights, analysis, and automation to its customers.
DOCU's total revenues increased 7% year-over-year to $736.03 million during the second quarter that ended on July 31, 2024. It reported non-GAAP income from operations of $237.16 million, indicating growth of 39.6% year-over-year. The company's non-GAAP free cash flow grew 7.8% from the year-ago value to $197.93 million.
Additionally, the company's non-GAAP net income came in at $200.99 million and $0.97 per share, up 34.3% and 34.7% from the prior year's quarter, respectively.
According to the company's fiscal year 2025 outlook, DOCU expects total revenue between $2.94 billion and $2.95 billion, while it forecasts subscription revenue to range from $2.86 billion to $2.88 billion.
For the third quarter (ending October 2024), analysts expect DOCU's revenue to grow 6.4% year-over-year to $745.32 million. For the same period, the company's EPS is expected to increase 10.6% year-over-year to $0.87. Also, it has surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
DOCU's stock has surged 22.9% over the past six months and 80.9% over the past year to close the last trading session at $70.15.
DOCU's POWR Ratings reflect its promising prospects. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
DOCU has an A grade for Quality and a B grade for Growth and Value. It is ranked #2 among 18 stocks in the same industry.
In addition to the POWR Ratings I've just highlighted, you can see DOCU's ratings for Stability, Momentum, and Sentiment <a href="https://stocknews.com/stock/DOCU/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
DOCU shares were trading at $68.98 per share on Wednesday afternoon, down $1.17 (-1.67%). Year-to-date, DOCU has gained 16.03%, versus a 23.16% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/docu-path-cccs-3-high-growth-saas-stocks-to-watch-in-november/>3 High-Growth SaaS Stocks to Watch in November</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Growth SaaS Stocks to Watch in November

The post-election uncertainties surrounding President-elect Donald Trump's proposals have fueled economic volatility. In these turbulent times, investing in stocks positioned for strong growth, such as UiPath (PATH), ExlService Holdings (EXLS), and Avanos Medical (AVNS), could be a smart move for investors seeking stability and long-term potential. Read on… With U.S. President-elect Donald Trump set to take office, the post-election landscape brings a wave of uncertainties about future policies. Rising geopolitical tensions have amplified market volatility, creating a challenging environment for investors. Amid this, choosing stable growth stocks stands out as a wise, resilient investment strategy.
Investors seeking stability might look to UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>), ExlService Holdings, Inc. (<a href="https://stocknews.com/stock/EXLS/">EXLS</a>), and Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>). Priced affordably under $50, these stocks offer strong growth potential and a lower entry cost. These companies have a robust foundation that makes them reliable choices during economic ups and downs.
Trump's second term arrives with significant implications for global trade, climate policy, and international relations. His proposed tariffs, <a href="https://www.aljazeera.com/economy/2024/11/6/trumps-likely-re-election-plunges-global-economy-into-uncertainty">at least 60% on Chinese imports</a> and 10–20% on other foreign goods vows to reshape the economic landscape, raising costs and impacting global growth. For businesses, this shift means adapting to a new era of trade dynamics.
Trump also vows to address high-profile international conflicts, pledging to resolve crises involving Israel, Hamas, and Hezbollah and to end the Russia-Ukraine war within 24 hours of taking office. Regardless of the outcomes, these shifts in global power dynamics would impact businesses worldwide, as geopolitical tension often mirrors fluctuations in the stock market.
Amid these uncertainties, <a href="https://www.investopedia.com/terms/g/growthstock.asp">growth stocks</a> offer a compelling solution. Known for above-average revenue growth, these companies often reinvest profits to fuel future expansion, making them attractive to long-term investors. In times of economic unpredictability, these growth-oriented stocks could provide a path to potentially steady gains.
So, let us dive deep into the fundamentals of three growth stocks, starting with #3.
Stock #3: UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>)
PATH is an AI-software and enterprise automation company specializing in building and managing automations and computer vision technology. It offers customers capabilities to automate using a digital workforce, collaborating with humans and operating mission-critical automation programs at scale.
On October 23, PATH <a href="https://ir.uipath.com/news/detail/370/omega-healthcare-processes-60-million-transactions-with-enterprise-ai-and-automation-from-uipath">announced the transformation of operations</a> for Omega Healthcare, a global leader in revenue cycle management, healthcare, and clinical enablement services, through its AI-powered automation. The partnership could position PATH as a frontrunner in AI-driven automation.
On October 22, PATH <a href="https://ir.uipath.com/news/detail/364/uipath-and-inflection-ai-announce-partnership-to-bring-agentic-ai-to-security-focused-industries">announced a strategic partnership</a> with Inflection AI, an enterprise AI company, to introduce the UiPath Platform with the new Inflection for Enterprise solution that would result in achieving higher operational efficiency and effectiveness for enterprises.
Through this partnership, PATH could reinforce its commitment to secure and efficient AI-driven solutions, positioning itself as a leader in innovative enterprise automation.
For the fiscal 2025 second quarter ended July 31, 2024, PATH's total revenue increased 10.1% year-over-year to $316.25 million. Its non-GAAP gross profit rose 6.6% from the year-ago value to $263.19 million. Additionally, the company's non-GAAP net income and non-GAAP net income per share came in at $23.76 million and $0.04, respectively.
Analysts expect PATH's revenue and <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> for the fiscal year ending January 2026 to increase 11% and 10.6% year-over-year to $1.58 billion and $0.44, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
Shares of PATH have surged 9.4% over the past month and 22.2% over the past six months to close the last trading session at $13.89.
PATH's robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
PATH has a B grade for Quality. It is ranked #11 out of 18 stocks in the A-rated <a href="https://stocknews.com/category/software-saas/">Software – SAAS</a> industry.
Beyond what is stated above, we've also rated PATH for Value, Momentum, Stability, Growth, and Sentiment. Get all PATH ratings <a href="https://stocknews.com/stock/PATH/">here</a>.
Stock #2: ExlService Holdings, Inc. (<a href="https://stocknews.com/stock/EXLS/">EXLS</a>)
EXLS is a data analytics and digital operations company that partners with clients using a data and AI-led approach. The company's four operational segments include: Insurance; Healthcare; Analytics; and Emerging Business.
On October 28, EXLS <a href="https://ir.exlservice.com/news-releases/news-release-details/exl-enterprise-ai-platform-accelerates-generative-ai-development">announced the launch</a> of its EXL Enterprise AI Platform, a technology hub created to aid the rapid-scale development and integration of GenAI solutions into client workflows.
By streamlining AI adoption, EXLS can anticipate solid growth through expanded service offerings, attracting more clients, and increasing revenue via scalable AI-driven efficiencies.
On October 17, EXLS <a href="https://ir.exlservice.com/news-releases/news-release-details/convex-partners-exl-accelerate-operational-excellence-through">announced a partnership</a> with Convex Group Limited, an international specialty insurer and reinsurer, for a multiyear engagement focused on accelerating the delivery of its business operations. The collaboration is expected to support EXLS's growth and strengthen its industry expertise and market position.
For the fiscal 2024 third quarter that ended September 30, EXLS' net revenues increased 14.9% year-over-year to $472.07 million. Its adjusted operating income rose 14.5% from the year-ago value to $94.09 million. Plus, the company's adjusted EBITDA increased 15.3% year-over-year to $104.44 million.
In addition, EXLS' adjusted net income and adjusted EPS grew 13.2% and 18.9% from the prior year's quarter to $71.02 million and $0.44, respectively.
The consensus revenue and EPS estimates of $476.26 million and $0.41 for the fiscal fourth quarter ending December 2024 reflect a year-over-year rise of 15% and 18.5%, respectively. Also, the company surpassed the consensus revenue and EPS estimates in all four trailing quarters.
EXLS' shares have gained 53.1% over the past six months and 74.6% over the past year, closing the last trading session at $46.90.
EXLS' sound prospects are projected in its POWR Ratings. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system.
EXLS has a B grade in Growth, Stability, and Quality. It is ranked #16 out of 39 stocks in the B-rated <a href="https://stocknews.com/category/outsourcing-business-services/">Outsourcing - Business Services</a> industry.
<a href="https://stocknews.com/stock/EXLS/">Click here</a> to access EXLS' ratings for Value, Momentum, and Sentiment.
Stock #1: Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>)
AVNS is a medical technology company offering a range of chronic care products, including digestive health solutions. It also provides non-opioid pain management options and interventional pain solutions focused on minimally invasive therapies for effective pain relief.
On November 5, AVNS <a href="https://avanos.investorroom.com/2024-11-05-Avanos-Medical-Launches-New-CORGRIP-R-SR">announced the launch</a> of CORGRIP SR Nasogastric/Nasointestinal Tube Retention System. The new launch expands the company's comprehensive Enteral Feeding portfolio and could strengthen AVNS's market presence by offering improved patient care solutions.
On June 19, AVNS <a href="https://avanos.com/industry-news/avanos-medical-inc-announces-agreement-to-acquire-diros-technology-inc/">announced a definitive agreement</a> to acquire Diros Technology Inc., a top manufacturer of advanced radiofrequency products for chronic pain treatment. The acquisition could broaden AVNS's pain management portfolio, enhance its capabilities in addressing chronic pain, and strengthen the company's position in the market.
For the fiscal third quarter that ended September 30, 2024, AVNS' net sales came in at $170.40 million. Its operating income increased 900% year-over-year to $12 million. Moreover, the company's adjusted net income and adjusted EPS were reported to be $15.10 million and $0.33, respectively.
As of September 30, 2024, AVNS' cash and cash equivalents amounted to $89 million, up from $87.70 million as of December 31, 2023.
Street expects AVNS' revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 2.3% and 24% year-over-year to $177.23 million and $0.40, respectively. Furthermore, the company surpassed the consensus revenue estimates in three of the four trailing quarters.
Shares of AVNS have gained 5.7% over the past six months and 8.8% over the past nine months, closing the last trading session at $20.69.
AVNS' positive fundamentals are mirrored in its POWR Ratings. The stock has an overall rating of B, translating to a Buy in our proprietary rating system.
AVNS has an A grade for Value and a B for Growth. It is ranked #17 out of 137 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry.
<a href="https://stocknews.com/stock/AVNS/">Click here</a> to access AVNS' ratings for Momentum, Sentiment, Quality, and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
PATH shares fell $13.89 (-100.00%) in premarket trading Tuesday. Year-to-date, PATH has declined -44.08%, versus a 27.16% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/path-exls-avns-3-top-growth-stocks-under-50-to-buy-now/>3 Top Growth Stocks Under $50 to Buy Now</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Top Growth Stocks Under $50 to Buy Now

ARKK's holdings ranked by SA Quant Grades

With trends like cloud computing and AI integration rising, mid-cap tech stocks offer strong potential upside with a unique blend of growth and adaptability. Thus, you might consider investing in midcap tech space, such as Open Text Corp (OTEX), Informatica (INFA), and UiPath (PATH), which have strong upside potential. Continue reading… In the world of <a href="https://www.investopedia.com/terms/m/midcapstock.asp">mid-cap stocks</a>, companies with a market cap between $2 billion and $10 billion are gaining attention on Wall Street as the next frontier for growth. These companies often have more flexibility and adaptability than large-cap stocks. However, in the tech sector, the mid-cap's agility and robust products make it an appealing opportunity to investors.
Below I have highlighted three mid-cap tech stocks: Open Text Corporation (<a href="https://stocknews.com/stock/OTEX/">OTEX</a>), Informatica Inc. (<a href="https://stocknews.com/stock/INFA/">INFA</a>), and UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>), which have more than 10% upside potential.
With Trump's victory and return to the White House for the second time, it is anticipated that the technology sector will benefit as it did in Trump's first term, helped by the administration's tax policies.
Trump's campaign has already hinted at plans to review the AI Executive Order and suggested <a href="https://www.forbes.com/sites/emilsayegh/2024/11/11/what-trumps-second-presidency-means-for-ai-crypto-and-cybersecurity/">strengthening the nation's AI infrastructure</a>, fostering an innovation-friendly environment for national security and economic dominance.
Furthermore, tech companies have been benefitting from emerging trends, especially in fields such as cloud computing, cybersecurity, and artificial intelligence. Technology stocks have been <a href="https://www.usbank.com/investing/financial-perspectives/market-news/investing-in-tech-stocks.html">outperforming the broader S&amp;P 500</a>, with Information technology stocks being the largest sector, comprising 32% of the S&amp;P 500 Index.
Additionally, mid-cap tech companies generally exhibit higher volatility, which means they can deliver significant returns if timed well, albeit with some inherent risks. Its growth is also being spurred by increased investor interest as these stocks often trade at a more accessible price point than large-cap tech, making it more appealing.
With that in mind, let's dig deeper into the fundamentals of the above-mentioned mid-cap stocks in detail:
Open Text Corporation (<a href="https://stocknews.com/stock/OTEX/">OTEX</a>)
Headquartered in Waterloo, Canada, with a market cap of $8.12 billion, OTEX provides information management products and services. It provides software solutions and content services, including content collaboration and intelligent capture to records management, collaboration, e-signatures, and archiving.
On October 21, OTEX announced a strategic partnership with Cork Inc. to add cyber warranty solutions and provide a holistic solution portfolio tailored specifically for Small and Medium Businesses (SMBs) and Managed Service Providers (MSPs). This collaboration empowers MSPs with financial protection, increased revenue streams, and improved client retention while reducing costs.
On September 5, OTEX announced a partnership with Nippon Gases Deutschland, the German business unit of Nippon Sanso Holdings Corporation (NSHD). This partnership enables Nippon to effectively manage the complexities of evolving e-invoicing mandates in Germany through OTEX's advanced cloud-based solutions.
For the first quarter of 2025, which ended on September 30, OTEX's total revenues stood at $1.27 billion, while its Cloud services and subscriptions segment reported a total revenue of $457.02 million, up marginally year-over-year.
In addition, the company's attributable net income stood at $84.42 million, indicating a 4.3% growth from the prior-year quarter period, while its <a href="https://www.investopedia.com/terms/e/eps.asp">earnings per share</a> came in at $0.32, up 6.7% year-over-year.
Analysts expect OTEX's revenue and EPS for the current year (ending June 2025) to be $5.31 billion and $3.66, respectively. For the fiscal year 2026, its revenue and EPS are expected to grow by 2.4% and 13.5% from the prior year to $5.44 billion and $4.15, respectively.
OTEX shares have surged 2.4% over the past three months to close the last trading session at $30.49.
OTEX's Wall Street analyst-given 12-month median price target of $34.17 indicates <a href="https://www.tipranks.com/stocks/otex/forecast">a 12.1% upside potential</a> from the last closing price. The price targets range from a low of $32 to a high of $38.
OTEX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
OTEX has an A grade for Value and a B for Growth. It is ranked #16 out of 129 stocks in the <a href="https://stocknews.com/category/software-application/">Software - Application</a> industry. <a href="https://stocknews.com/stock/OTEX/">Click here</a> to see the additional ratings for OTEX (Momentum, Stability, Sentiment, and Quality).
Informatica Inc. (<a href="https://stocknews.com/stock/INFA/">INFA</a>)
With a market cap of $7.78 billion, INFA is an enterprise cloud data management company that develops an artificial intelligence-powered platform that connects, manages, and unifies data across multi-vendor, multi-cloud, and hybrid systems at enterprise scale internationally. 
On November 12, INFA announced the expansion of the GenAI-powered data management assistant, CLAIRE&#xAE; GPT, in Europe and the Asia Pacific (APAC) regions, followed by its launch in North America this year.
This expansion will enable customers more flexibility and accessibility to leverage GenAI-powered data management capabilities. It will also allow INFA to set its footprint in the Asia Pacific region.
On September 12, INFA announced that Ricoh Company, Ltd., a leading provider of document management solutions, selected its Intelligent Data Management Cloud&#x2122; (IDMC) to accelerate Ricoh's GLIDER data infrastructure project to support the overall business transformation of Ricoh becoming a digital services company.
In the fiscal second quarter (which ended on June 30), INFA's total revenues increased 3.4% year-over-year to $422.48 million. Its non-GAAP income from operations improved 18% from the year-ago value to $151.04 million. The company's non-GAAP net income came in at $88.95 million and $0.28 per share, indicating growth of 10.3% and 3.7% year-over-year, respectively.
Furthermore, the company's adjusted EBITDA increased 17.1% from the prior year's quarter to $154.79 million, and its adjusted free cash flow grew 85.5% from the year-ago value to $107.78 million.
According to the company's financial guidance for the full year 2024, INFA now forecasts revenue to be range of $1.66 billion-$1.68 billion and its non-GAAP operating income to range from $538 million-$558 million. The company also expects adjusted unlevered free cash flow to be between $545 million and $565 million.
The consensus revenue estimate of $457.09 million for the fiscal fourth quarter (ending December 2024) represents a 2.7% increase year-over-year. The consensus EPS estimate of $0.38 for the current quarter indicates a 17.5% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS in three of the trailing four quarters.
Over the past year, the stock has surged 8.9%, closing the last trading session at $25.47.
Based on eight Wall Street analysts offering 12-month price targets for INFA in the last three months, <a href="https://www.tipranks.com/stocks/infa/forecast">the average target price is $33.38</a>, indicating a 31.1% change from the last price, with a high forecast of $37 and a low forecast of $27.
INFA's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth and Quality. Within the A-rated <a href="https://stocknews.com/category/software-saas/">Software - SAAS</a> industry, it is ranked #6 out of 18 stocks. <a href="https://stocknews.com/stock/INFA/">Click here</a> to see INFA's ratings for Value, Momentum, Stability, and Sentiment.
UiPath Inc. (<a href="https://stocknews.com/stock/PATH/">PATH</a>)
PATH is an enterprise automation and AI software company that provides an end-to-end automation platform that offers a variety of international Robotic Process Automation (RPA) solutions. It has a market cap of $7.44 billion.
On October 23, PATH announced the transformation of operations for Omega Healthcare, a global leader in revenue cycle management, healthcare, and clinical enablement services, through its AI-powered automation. The partnership could position PATH as a frontrunner in AI-driven automation and deliver significant outcomes.
On October 22, PATH announced a strategic partnership with Inflection AI to integrate the UiPath Platform with the new Inflection for Enterprise solution, allowing enterprises to achieve more operational efficiency and effectiveness without compromising trust and AI security options.
This partnership will provide PATH with a significant private cloud alternative for agentic automation tailored to the industries with the most stringent security requirements.
PATH's revenues for the second quarter (ended July 31, 2024) increased 10.1% year-over-year to $316.25 million. It reported a non-GAAP gross profit of $263.19 million, indicating a 6.6% growth from the prior-year quarter, while its non-GAAP net income for the quarter stood at $23.76 million or $0.04 per share. Also, the company's non-GAAP adjusted free cash flow increased 25.6% year-over-year, amounting to $149.78 million.
As per the financial outlook for the fiscal year 2025, PATH forecasts revenue to be between $1.42 billion and $1.43 billion. The company also expects a non-GAAP operating income of approximately $170 million.
Street expects PATH's EPS for the fiscal year 2026 to increase 10.6% year-over-year to $0.44. Its revenue for the same year is expected to grow 11% year-over-year to $1.58 billion.
Shares of PATH have gained 17.4% over the past year to close the last trading session at $13.53.
Based on 17 Wall Street analysts offering 12-month price targets for PATH in the last three months, <a href="https://www.tipranks.com/stocks/path/forecast">the average target price is $15.75</a>, indicating a 16.4% change from the last price, with a high forecast of $19 and a low forecast of $13.
It's no surprise that PATH has an overall rating of B, which equates to a Buy in our POWR Ratings system. It has a B grade for Growth and Quality. Out of 18 stocks in the Software - SAAS industry, PATH is ranked #10.
Beyond what is stated above, we've also rated PATH for Value, Momentum, Stability, and Sentiment. Get all PATH ratings <a href="https://stocknews.com/stock/PATH/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
OTEX shares were trading at $29.35 per share on Thursday afternoon, down $1.14 (-3.74%). Year-to-date, OTEX has declined -27.87%, versus a 26.32% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/otex-infa-path-3-mid-cap-tech-stocks-wall-street-expects-to-gear/>3 Mid-Cap Tech Stocks Wall Street Expects to Gear</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Mid-Cap Tech Stocks Wall Street Expects to Gear

UiPath: Will Become A Different Company

UiPath: The Hidden Gem In Robotic Process Automation Worth Buying Now

In a report released on November 17, Matthew Hedberg from RBC Capital maintained a Hold rating on UiPath (PATH – Research Report), with a price tar...

UiPath (PATH) Receives a Rating Update from a Top Analyst

Bullish option flow detected in UiPath (PATH) with 15,182 calls trading, 2x expected, and implied vol increasing over 1 point to 79.60%. 12/6 weekl...

Comments

UiPath

Vendite allo scoperto

UiPath (NYSE:PATH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO